Clocard-A75 mg+75 mg

Clocard-A 75 mg+75 mg is a fixed-dose dual antiplatelet combination used to reduce the risk of serious cardiovascular events in patients at high thrombotic risk.

• Established/FDA-approved: Acute coronary syndrome (ACS), including non-ST-segment elevation ACS (unstable angina/NSTEMI) and ST-segment elevation myocardial infarction (STEMI), to reduce the rate of myocardial infarction and stroke.
• Established/FDA-approved: Patients who have undergone percutaneous coronary intervention (PCI) with coronary artery stenting, to reduce the risk of stent thrombosis.
• Guideline-supported: Secondary prevention of atherothrombotic events (myocardial infarction, stroke, or vascular death) in patients with recent myocardial infarction, recent ischemic stroke, or established peripheral arterial disease.
• Requires-combo/adjunct use: Both components must be taken together as directed, alongside other guideline-based therapies (e.g., statins, beta-blockers) for coronary or cerebrovascular disease, per the treating physician's plan.

Clocard-A 75 mg+75 mg should only be used for the indication and duration specifically prescribed by a physician, since the two components carry different individual risk-benefit profiles that must be balanced for each patient.

Clocard-A 75 mg+75 mg is available as a fixed-dose combination tablet, most commonly containing clopidogrel bisulfate equivalent to 75 mg clopidogrel base together with 75 mg aspirin. Other strength combinations (for example, clopidogrel 75 mg with aspirin 150 mg) may also be marketed; the exact strength of Clocard-A 75 mg+75 mg prescribed should always be confirmed against the physician's prescription and the product label.

Clocard-A 75 mg+75 mg combines two antiplatelet medicines with complementary mechanisms of action into a single tablet, a strategy commonly known as dual antiplatelet therapy (DAPT). Clopidogrel is a thienopyridine prodrug that irreversibly blocks the P2Y12 adenosine diphosphate (ADP) receptor on platelets, while aspirin irreversibly inhibits platelet cyclooxygenase-1 (COX-1), reducing thromboxane A2 production. Together they provide more potent inhibition of platelet aggregation than either agent alone, which is why Clocard-A 75 mg+75 mg is widely used after heart attack, ischemic stroke, and coronary stent placement to prevent further clot-related events.

Clocard-A 75 mg+75 mg belongs to the antiplatelet agent class, specifically combining a P2Y12 receptor inhibitor (thienopyridine) with a cyclooxygenase (COX) inhibitor, and is used as part of dual antiplatelet therapy (DAPT).

Clocard-A 75 mg+75 mg acts through two complementary antiplatelet mechanisms.

• Clopidogrel is a prodrug that requires hepatic activation, primarily via the CYP2C19 enzyme, to form an active metabolite. This active metabolite irreversibly binds to the P2Y12 class of ADP receptors on the platelet surface, preventing ADP-mediated activation of the glycoprotein GPIIb/IIIa complex and thereby inhibiting platelet aggregation for the lifespan of the platelet (approximately 7-10 days).
• Aspirin irreversibly acetylates and inhibits platelet cyclooxygenase-1 (COX-1), blocking the conversion of arachidonic acid to thromboxane A2, a potent platelet activator and vasoconstrictor. This effect also lasts for the life of the platelet.

Because the two agents act on separate pathways, Clocard-A 75 mg+75 mg produces a greater overall reduction in platelet aggregation than either component alone, which underlies its use in preventing stent thrombosis and recurrent atherothrombotic events.

Clocard-A 75 mg+75 mg is taken by mouth once daily, with or without food, swallowed whole with a full glass of water. It should be taken at the same time each day to maintain a consistent antiplatelet effect. Do not crush, chew, or split the tablet unless specifically instructed by the physician or pharmacist. See Dosage and Administration for indication-specific regimens.

Clocard-A 75 mg+75 mg has clinically important interactions that require caution:

• Strong CYP2C19 inhibitors (e.g., omeprazole, esomeprazole): These drugs reduce conversion of clopidogrel to its active metabolite and can significantly lower the antiplatelet effect of Clocard-A 75 mg+75 mg. Concomitant use with omeprazole or esomeprazole should generally be avoided; if gastric acid suppression is needed, a proton pump inhibitor with less CYP2C19 inhibition, such as pantoprazole, may be considered instead, per the physician's guidance.
• Anticoagulants (warfarin, heparin, direct oral anticoagulants): Concomitant use with Clocard-A 75 mg+75 mg increases bleeding risk and requires close medical supervision; safety of combined use has not been well established for routine practice.
• NSAIDs (e.g., ibuprofen, naproxen): Increase the risk of gastrointestinal bleeding when taken with Clocard-A 75 mg+75 mg and should be used only if advised by the physician.
• Other antiplatelet agents: Combining additional antiplatelet drugs with Clocard-A 75 mg+75 mg further increases bleeding risk and should only be done under specialist supervision.
• SSRIs/SNRIs: May increase bleeding risk when combined with Clocard-A 75 mg+75 mg due to effects on platelet function.

Patients should tell their physician and pharmacist about all medicines, supplements, and herbal products being taken before starting or continuing Clocard-A 75 mg+75 mg.

The most common adverse effect of Clocard-A 75 mg+75 mg is increased bleeding tendency, ranging from minor to serious (see Precautions and Warnings for major bleeding risk). Other reported side effects include:

• Bruising and prolonged bleeding from minor cuts
• Epistaxis (nosebleed)
• Gastrointestinal upset, including dyspepsia, abdominal pain, and nausea
• Diarrhea or constipation
• Skin rash or itching
• Headache and dizziness

Less common but serious effects can include gastrointestinal bleeding, hematuria, and, rarely, thrombotic thrombocytopenic purpura (TTP) or severe hypersensitivity reactions such as angioedema. Any unusual bleeding, black or bloody stools, blood in urine, or signs of allergic reaction while taking Clocard-A 75 mg+75 mg should be reported to a physician immediately.

Pregnancy: Clocard-A 75 mg+75 mg should be used during the first and second trimesters of pregnancy only if the potential benefit clearly justifies the potential risk to the fetus, and only under close physician supervision. Clocard-A 75 mg+75 mg is contraindicated during the third trimester of pregnancy, as aspirin at this stage is associated with risks including premature closure of the fetal ductus arteriosus and increased bleeding risk around delivery.

Lactation: It is not well established whether clopidogrel or its metabolites pass into human breast milk, but aspirin does pass into breast milk. Because of the potential for adverse effects in the nursing infant, including bleeding risk and Reye's syndrome-type concerns, breastfeeding should generally be discontinued while taking Clocard-A 75 mg+75 mg, unless the physician advises otherwise after weighing the maternal need for therapy against infant risk.

Bleeding risk: Clocard-A 75 mg+75 mg increases the risk of bleeding, including serious and occasionally fatal gastrointestinal bleeding and intracranial hemorrhage, because both components inhibit platelet function. Patients should watch for unusual bruising, prolonged bleeding, black/bloody stools, or blood in urine or vomit, and seek prompt medical attention if these occur.

Do not stop without medical advice: Clocard-A 75 mg+75 mg must not be stopped or doses skipped without first consulting the prescribing physician. This is especially critical in patients who have recently received a coronary stent, because premature discontinuation of dual antiplatelet therapy substantially increases the risk of stent thrombosis, heart attack, and death. The full course of Clocard-A 75 mg+75 mg, including its exact duration, should be taken exactly as prescribed.

Before surgery or dental procedures: Patients should inform every treating doctor, dentist, or surgeon that they are taking Clocard-A 75 mg+75 mg, since it may need to be temporarily held before elective procedures with significant bleeding risk. Any interruption of Clocard-A 75 mg+75 mg before a procedure should be planned and timed only by the treating physician, and therapy should be resumed as soon as the physician advises.

CYP2C19 poor metabolizers: Patients with reduced CYP2C19 enzyme activity (more common in some Asian populations) may form less active metabolite from the clopidogrel component and could have a reduced antiplatelet response to Clocard-A 75 mg+75 mg; the physician may consider alternative therapy or testing in select high-risk patients.

Thrombotic thrombocytopenic purpura (TTP): A rare but serious and potentially fatal condition has been reported with clopidogrel-containing products, sometimes after short exposure, presenting with thrombocytopenia, hemolytic anemia, neurological symptoms, kidney impairment, and fever; this requires urgent medical evaluation.

Reye's syndrome: Because Clocard-A 75 mg+75 mg contains aspirin, it should not be given to children or teenagers with chickenpox, influenza, or other viral illnesses due to the risk of Reye's syndrome.

Hypersensitivity: Rash, angioedema, or other hypersensitivity/anaphylactoid reactions, including cross-reactivity between clopidogrel and other thienopyridines, have been reported.

Overdose of Clocard-A 75 mg+75 mg is a medical emergency. Excess clopidogrel prolongs bleeding time and increases the risk of bleeding complications; because its antiplatelet effect is irreversible, platelet transfusion may be needed to help restore normal clotting if serious bleeding occurs. Excess aspirin can cause symptoms ranging from tinnitus (ringing in the ears), headache, dizziness, nausea, and vomiting at lower overdose levels to more severe effects such as hyperventilation, fever, confusion, seizures, and metabolic acidosis at higher levels, and may require interventions including activated charcoal, intravenous fluids, or hemodialysis in severe cases. Anyone who has taken more than the prescribed dose of Clocard-A 75 mg+75 mg, or who shows signs of bleeding or salicylate toxicity, should seek immediate medical attention or contact emergency services/a poison control center without delay.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: No specific dose adjustment of Clocard-A 75 mg+75 mg is generally required based on age alone, but elderly patients may have a higher baseline bleeding risk and should be monitored closely.

Renal impairment: Limited clinical experience is available in patients with severe renal impairment; Clocard-A 75 mg+75 mg should be used with caution and physician oversight in this group.

Hepatic impairment: Clocard-A 75 mg+75 mg should be used with caution in moderate hepatic disease and is contraindicated in severe hepatic impairment with bleeding tendency (see Contraindications).

Pediatric population: Safety and effectiveness of Clocard-A 75 mg+75 mg have not been well established in children; see Pediatric Uses.

Pregnancy and breastfeeding: See Pregnancy and Lactation for full detail.

The duration of treatment with Clocard-A 75 mg+75 mg is individualized and must be determined by the treating physician based on the indication, the type of coronary stent (if any), and the patient's bleeding versus clotting risk. For dual antiplatelet therapy after coronary stenting, treatment commonly continues for 6 to 12 months, though shorter or longer courses may be prescribed in specific circumstances. Patients must never stop Clocard-A 75 mg+75 mg early or extend treatment beyond the prescribed period without the physician's explicit instruction, since premature discontinuation—particularly soon after stent placement—carries a serious risk of stent thrombosis, heart attack, or death.

Clocard-A 75 mg+75 mg is classified as an antiplatelet agent combination: a P2Y12 receptor inhibitor of the thienopyridine class (clopidogrel) combined with a cyclooxygenase (COX-1) inhibitor (aspirin), together forming a dual antiplatelet therapy (DAPT) regimen.

Clocard-A 75 mg+75 mg works through two complementary, irreversible antiplatelet mechanisms: clopidogrel blocks the platelet P2Y12 ADP receptor, and aspirin inhibits platelet cyclooxygenase-1 to reduce thromboxane A2 production. Together these actions produce more effective inhibition of platelet aggregation than either drug alone (see Pharmacology for full mechanistic detail).

Category C (first and second trimester); use in the third trimester is contraindicated.

The safety and effectiveness of Clocard-A 75 mg+75 mg in children have not been well established, and its use in pediatric patients is generally not recommended except under specialist direction when the potential benefit is judged to clearly outweigh the risk. Clocard-A 75 mg+75 mg must not be given to children or teenagers under 16 years of age who have, or are recovering from, chickenpox, influenza, or other viral illness, because the aspirin component carries a risk of Reye's syndrome, a rare but potentially fatal condition affecting the liver and brain. Any decision to use Clocard-A 75 mg+75 mg in a child must be made and closely supervised by a pediatric specialist or cardiologist.